Venetoclax activity in CLL patients who have relapsed after or are refractory to ibrutinib or idelalisib.
Jeffrey A. Jones(The Ohio State University), Steven Coutré(Georgetown University), Ahmad Halwani(University of Utah), Paul M. Barr(University of Rochester Medical Center), Rod Humerickhouse(Abbott Fund), Matthew S. Davids(Dana-Farber Cancer Institute), Leonard T. Heffner(Emory University), Brenda Chyla(AbbVie (United States)), Herbert Eradat(University of Colorado Cancer Center), Michael Y. Choi(University of California San Diego), Bruce D. Cheson(Center for Cancer and Blood Disorders), Anthony R. Mato(Memorial Sloan Kettering Cancer Center), Ming Zhu(AbbVie (United States)), William G. Wierda(University of Maryland, Baltimore), Jalaja Potluri(AbbVie (United States)), Nicole Lamanna(Memorial Sloan Kettering Cancer Center), Maria E. Verdugo(AbbVie (United States)), Richard R. Furman(Cornell University)
Cited by 22
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
|Journal of Clinical Oncology|2003|2.7k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k